Epidermal growth factor receptor tyrosine kinase inhibitors

被引：76

作者：

Wakeling, AE ^{[1
]}

机构：

[1] AstrZeneca Pharmaceut, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2002年 / 2卷 / 04期

关键词：

D O I：

10.1016/S1471-4892(02)00183-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Clinical trials of selective small-molecule, inhibitors of epidermal growth factor receptor tyrosine kinase activity have shown that these targeted inhibitors of proliferative signal transduction provide well-tolerated antitumour activity in patients. Preclinical pharmacology studies illustrate the potential use of these new cancer therapeutics in combination with chemotherapy, radiotherapy and hormone therapy, and in chemoprevention, in a spectrum of solid human tumours.

引用

页码：382 / 387

页数：6

共 48 条

[41]

Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885

[42] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

[43] Cl-1033, a pan-erbB tyrosine kinase inhibitor [J].

Slichenmyer, WJ ;

Elliott, WL ;

Fry, DW .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :80-85

[44] Combinatorial chemoprevention of intestinal neoplasia [J].

Torrance, CJ ;

Jackson, PE ;

Montgomery, E ;

Kinzler, KW ;

Vogelstein, B ;

Wissner, A ;

Nunes, M ;

Frost, P ;

Discafani, CM .

NATURE MEDICINE, 2000, 6 (09) :1024-1028

[45]

Tortora G, 2001, CLIN CANCER RES, V7, P4156

[46]

Wakeling AE, 2001, CLIN CANCER RES, V7, p4350S

[47]

WILLIAMS KJ, 2001, P AM ASSOC CANC RES, V42, P3840

[48] Untangling the ErbB signalling network [J].

Yarden, Y ;

Sliwkowski, MX .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :127-137

← 1 2 3 4 5 →